22419-35-8

Usage

Uses

Used in Pharmaceutical Industry:
4,4-Difluorocyclohexanol is used as a reagent for the clearance of adenosine inhibitors of bacterial NAD+-dependent DNA ligase. This application is significant in the development of new antibiotics and the study of bacterial DNA repair mechanisms, contributing to the advancement of medical treatments and understanding of bacterial resistance.
Used in Chemical Synthesis:
As a versatile reagent, 4,4-Difluorocyclohexanol is employed in the synthesis of various chemical compounds. Its unique properties allow it to be a key component in the creation of new molecules with potential applications in different industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C6H10F2O/c7-6(8)3-1-5(9)2-4-6/h5,9H,1-4H2

Upstream product

• 22515-18-0 4,4-difluorocyclohexanone 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 23510-95-4 4-benzoyloxycyclohexanone 
• 556-48-9 1,4-Cyclohexanediol 
• 22419-33-6 (4.4-Difluor-cyclohexyl)-benzoat 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 176251-49-3 8,8-difluoro-1,4-dioxaspiro[4,5]decane 
• 917383-03-0 4,4-difluoro-N-methoxy-N-methylcyclohexane-1-carboxamide 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 

Downstream Products

• 1154471-80-3 tert-butyl 8-[(4,4-difluorocyclohexyl)oxy]-2,3-dihydropyrido[3,2-f][1,4]oxazepine-4(5H)-carboxylate 
• 1312565-58-4 (RS)-3-[4-(4,4-difluoro-cyclohexyloxycarbonylamino)-phenyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1332633-14-3 2-(4,4-Difluoro-cyclohexyloxy)-4-fluoro-phenylamine 
• 1332633-13-2 2-(4,4-difluoro-cyclohexyloxy)-4-fluoro-1-nitro-benzene 
• 1355615-81-4 C₁₉H₂₅F₂N₅O₄ 
• 1361967-57-8 C₂₂H₂₁F₂NO₂ 
• 1473452-92-4 1-(2-(4,4-difluorocyclohexyloxy)-5-nitrophenyl)-3-methyl-6,7-dihydro-2H-isoindol-4(5H)-one 
• 1548290-87-4 4-(4,4-difluoro-cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidine-5-carbaldehyde 
• 1548290-03-4 3-[4-(4,4-difluoro-cyclohexyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-acrylamide 
• 1548590-10-8 (4,4-difluorocyclohexyl)hydrazine hydrogen chloride 

Relevant academic research and scientific papers

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

ANTI-BACTERIAL COMPOUNDS

A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS

The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.

4-Azaindole Derivatives

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

4-AZAINDOLE DERIVATIVES

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

Discovery of bacterial NAD+-dependent DNA ligase inhibitors: Improvements in clearance of adenosine series

Optimization of clearance of adenosine inhibitors of bacterial NAD +-dependent DNA ligase is discussed. To reduce Cytochrome P-450-mediated metabolic clearance, many strategies were explored; however, most modifications resulted in compounds wi

4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel thienopyrimidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.